MONMOUTH JUNCTION, N.J.,
April 14, 2015 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy company using blood purification to treat deadly
inflammation in critically-ill and cardiac surgery patients,
announced that Dr. Phillip Chan, MD,
PhD, Chief Executive Officer of CytoSorbents, will make a corporate
presentation at the 14th Annual Needham Healthcare
Conference at the Westin NY Grand Central Hotel in New York City, New York.
Dr. Chan will present from 5:00–5:40PM EDT on Wednesday, April 15, 2015. He will be
joined by Ms. Kathleen Bloch, Chief
Financial Officer, during the day for pre-scheduled one-on-one
meetings with institutional investors. A live audio webcast of the
presentation will be available at
http://wsw.com/webcast/needham71/ctso. An archived version of the
webcast will be available at http://www.cytosorbents.com/invest.htm
for 90 days.
The Company's flagship product, CytoSorb®, is the only
specifically approved extracorporeal cytokine adsorber in
Europe, targeting the reduction of
cytokines and other inflammatory mediators from blood that drive
deadly inflammation in life-threatening illnesses seen in the
intensive care unit, and in complex cardiac surgery.
CytoSorb® generated $3.1 million in
sales in 2014, an increase of 281% from 2013, with product gross
margins of 63%. CytoSorbents has established distribution of
CytoSorb® in 29 countries around the world, through a combination
of direct sales, independent distributor sales, as well as
partnerships with major international companies such as Fresenius
Medical Care, the world's largest dialysis company, Biocon Ltd,
Asia's largest biotechnology
company, and one of the largest global cardiac surgery
companies.
Needham's Healthcare Conference focuses on connecting leading
emerging life science companies and institutional investors.
This year, senior management teams from approximately 100 companies
in the biotechnology, specialty pharmaceutical, medical technology
and diagnostic sectors have been invited and scheduled to present.
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to control severe
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is
the cause of nearly half of all deaths in the intensive care unit,
with little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union with
distribution established in 29 countries around the world, as a
safe and effective extracorporeal cytokine adsorber, designed to
reduce the "cytokine storm" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses
such as sepsis, burn injury, trauma, lung injury, and pancreatitis.
These are conditions where the risk of death is extremely high, yet
no effective treatments exist. CytoSorb® is also being used
during and after cardiac surgery to remove inflammatory mediators,
such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website:
http://www.cytosorbents.com/.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 31, 2015, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and
Twitter
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-14th-annual-needham-healthcare-conference-300065293.html
SOURCE CytoSorbents Corporation